<DOC>
	<DOCNO>NCT02076386</DOCNO>
	<brief_summary>DOL-ART multi-center , prospective , non-interventional study use doluetegravir part antiretroviral combination therapy routine daily practice Germany . The primary study objective descriptive characterization frequency therapeutic monitoring measure HIV-infected patient dolutegravir-containing ART routine daily practice Germany . The study design enroll approximately 400 patient . There protocol-mandated visit procedure associate study . Each patient expect participate maximum 3 year premature discontinuation ( i.e. , discontinuation dolutegravir , due death , withdrawal consent , lose follow-up ) .</brief_summary>
	<brief_title>A Prospective , Non-interventional Study Use Dolutegravir Part Combination Antiretroviral Therapy Routine Daily Practice Germany</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Documented HIV infection Age â‰¥ 18 year Decision first initiation dolutegravir part ART attend physician irrespective inclusion observational study Prior start study , patient must receive dolutegravircontaining ART least 4 week Discontinuation dolutegravir part ART prior start study documentation Participation clinical trial study Participation clinical trial compassionate use program dolutegravir part investigational medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>